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Abstract
Background: The constant increase of cancer cell resistance to radio- and chemotherapy hampers improvement of patient
survival and requires novel targeting approaches. Integrin-Linked Kinase (ILK) has been postulated as potent druggable
cancer target. On the basis of our previous findings clearly showing that ILK transduces antisurvival signals in cells exposed
to ionizing radiation, this study evaluated the impact of the small molecule inhibitor QLT0267, reported as putative ILK
inhibitor, on the cellular radiation survival response of human head and neck squamous cell carcinoma cells (hHNSCC).
Methodology/Principal Findings: Parental FaDu cells and FaDu cells stably transfected with a constitutively active ILK
mutant (FaDu-IH) or empty vectors, UTSCC45 cells, ILK
floxed/floxed(fl/fl) and ILK
2/2 mouse fibroblasts were used. Cells grew
either two-dimensionally (2D) on or three-dimensionally (3D) in laminin-rich extracellular matrix. Cells were treated with
QLT0267 alone or in combination with irradiation (X-rays, 0–6 Gy single dose). ILK knockdown was achieved by small
interfering RNA transfection. ILK kinase activity, clonogenic survival, number of residual DNA double strand breaks (rDSB;
cH2AX/53BP1 foci assay), cell cycle distribution, protein expression and phosphorylation (e.g. Akt, p44/42 mitogen-activated
protein kinase (MAPK)) were measured. Data on ILK kinase activity and phosphorylation of Akt and p44/42 MAPK revealed a
broad inhibitory spectrum of QLT0267 without specificity for ILK. QLT0267 significantly reduced basal cell survival and
enhanced the radiosensitivity of FaDu and UTSCC45 cells in a time- and concentration-dependent manner. QLT0267 exerted
differential, cell culture model-dependent effects with regard to radiogenic rDSB and accumulation of cells in the G2 cell
cycle phase. Relative to corresponding controls, FaDu-IH and ILK
fl/fl fibroblasts showed enhanced radiosensitivity, which
failed to be antagonized by QLT0267. A knockdown of ILK revealed no change in clonogenic survival of the tested cell lines
as compared to controls.
Conclusions/Significance: Our data clearly show that the small molecule inhibitor QLT0267 has potent cytotoxic and
radiosensitizing capability in hHNSCC cells. However, QLT0267 is not specific for ILK. Further in vitro and in vivo studies are
necessary to clarify the potential of QLT0267 as a targeted therapeutic in the clinic.
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Introduction
The clinical administration of molecular targeted therapies as
monotherapy or in combination with radio- or chemotherapy is
constantly rising. Promising results have already been obtained in
chronic myeloid leukemia and gastrointestinal stromal tumors using
the BCR-ABL small molecule inhibitor GleevecH [1] or in head and
neck cancers using the inhibitory epidermal growth factor receptor
antibody ErbituxH [2]. In addition to the large plethora of
resistance-mediating influences such as gain-of-function mutations
in proto-oncogenes, elevated levels of hypoxia, and multidrug
resistance by p-glycoprotein overexpression [3–5], the importance
of adhesion-mediated drug resistance and adhesion-mediated
radioresistance has recently come to light [6–8].
As part of focal adhesion complexes, Integrin-Linked Kinase
(ILK) was recently introduced as potent cancer target [9]. ILK is
ubiquitously expressed, b1 and b3 integrin-bound protein with
critical functions in cytoskeletal integrin-actin connection and focal
adhesion formation [10]. ILK contains a C-terminal protein
kinase catalytic domain, a Pleckstrin homology-like domain and a
N-terminal domain, which consists of five Ankyrin repeats [11,12].
Latest observations showed a participation of the Ankyrin 2–5 of
ILK in the interaction of ILK with the LIM (Lin-1, Isl-1, Mec-3)1
domain of the LIM-only adapter protein PINCH1 (particularly
interesting new cysteine-histidine-rich protein) [12]. Although
biological and biochemical studies support the view that ILK is
fundamental for integrin-actin linkage and integrin-growth factor
receptor interactions [10,13–16], the protein kinase ability of ILK
is still controversial, which resulted in the classification of ILK as
pseudokinase [17,18].
The current notion of ILK as therapeutic target arose from both
in vitro and in vivo studies. In vitro, cell survival and proliferation
were shown to be regulated by ILK especially via the
Phosphatidylinositol-3 Kinase/Akt and Mitogen-Activated Protein
Kinase (MAPK) cascade [14,19,20]. The knockdown of ILK or a
pharmacological ILK inhibition using QLT0267 or one of its
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and adhesion [21–23]. Our own studies, however, clearly showed
a critical antisurvival role of ILK in cells exposed to ionizing
radiation [20,24–27]. Investigations using human A549 lung
cancer cells, FaDu hHNSCC cells, human HL60 leukemia cells or
mouse fibroblasts provided evidence that cells either overexpress-
ing a constitutively active kinase form of ILK or expressing a
wildtype form of ILK are significantly more sensitive to irradiation
than their normal or ILK knockout counterparts, respectively.
Histological studies in a variety of human tumors exhibited an
overexpression of ILK. Among these tumor entities were carcino-
mas from the ovary, colon, thyroid, melanoma, prostate, stomach
and lung [13,28–35]. A recent broad study using tissue microarray
technique questioned these results by showing similar ILK
expression in tumor tissue and normal tissue [36]. Intriguingly,
the same study also demonstrated a significant reduction of ILK
expression with increasing tumor grade of human kidney cancers.
Hence, this work suggested that ILK is tightly associated with
differentiation but not with dedifferentiation and/or carcinogenesis.
Owing to the controversial findings about the genetic and
pharmacological targeting of ILK, this study was performed to
evaluate the cytotoxic and radiosensitizing effects of the putative
pharmacological ILK inhibitor QLT0267 on clonogenic survival
and signal transduction of different hHNSCC cell lines. To more
precisely mimic a physiological growth environment, the treat-
ment was accomplished either when cells adhered to laminin-rich
extracellular matrix (lrECM) precoated dishes or when cells were
imbedded into a three-dimensional (3D) lrECM. From the
presented observations a broad but not ILK-specific inhibitory
spectrum can be concluded. QLT0267 exerted cytotoxic and
radiosensitizing effects in the tested cell lines in a concentration-
and time-dependent manner.
Results
QLT0267 inhibits ILK kinase activity in a cell line- and
culture model-dependent manner
To assure efficient ILK kinase inhibition by QLT0267, we
performed a kinase assay on immunoprecipitates from total cell
lysates of 2D and 3D lrECM cell cultures treated with different
QLT0267 concentrations over 1 h or 24 h. The data showed a
strongly reduced ILK kinase activity in both 2D grown FaDu and
UTSCC45 hHNSCC cell lines exposed to 1 mM QLT0267 as
compared to an equivalent volume of DMSO (Figure 1A). No
further ILK kinase inhibition was achieved when the dose was
increased to 10 mM indicating that the maximal inhibitory effect
of QLT0267 was already obtained at a concentration of 1 mM. In
3D, however, the inhibitory efficiency of QLT0267 on ILK was
reduced in FaDu in comparison to 2D FaDu cell cultures, whereas
in 3D UTSCC45 cells QLT0267 even exerted an inverse effect on
ILK kinase activity relative to 2D conditions (Figure 1B).
QLT0267 enhances the radiosensitivity of hHNSCC cells
As QLT0267 modulated ILK kinase activity, we next analyzed
the effect of QLT0267 on basal clonogenic survival and radiation
clonogenic survival of FaDu and UTSCC45 hHNSCC cells under
2D and 3D cell culture conditions. On the basis of our previous
studies [20,25–27], we expected a radioprotective effect by
QLT0267. A 1-h QLT0267 exposure showed no significant effect
on both basal and radiation cell survival (Figure 2A-C, Table 1).
Figure 1. QLT0267 modifies ILK kinase activity in cell culture model-dependent manner. (A)2 Do r( B) 3D cultured FaDu and UTSCC45
cells were exposed to 1 mMo r1 0mM QLT0267 (DMSO served as control) and lysed after 1 h or 24 h. After immunoprecipitation of ILK and incubation
with GSK fusion protein, samples were subjected to SDS-PAGE and Western blotting. Phosphorylation of GSK fusion protein with phospho-GSK3a/b
S21/9 antibody indicates ILK kinase activity. Fold changes were calculated from densitometry and normalized to ILK and DMSO controls.
doi:10.1371/journal.pone.0006434.g001
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(P,0.05) cytotoxicity (Fig. 2A and B) and radiosensitization of both
FaDu and UTSCC45cells to the clinical relevant radiation dose per
fraction of 2 Gy relative to DMSO controls (Figure 2C, Table 1).
Except in 3D FaDu cell cultures showing a 2.6-fold enhancement of
the cellular radiosensitivity under QLT0267 exposure, 2D FaDu
and 2D and 3D UTSCC45 cells were radiosensitized by QLT0267
bya factorof,1.5(Table1).Conclusively,neither the cytotoxic nor
the radiosensitizing effects mediated by QLT0267 could be
correlated with the changes in ILK kinase activity displayed in
figure 1. Further, QLT0267 failed to show a radioprotective effect,
which suggests a low or absent specificity for ILK.
Treatment with QLT0267 leads to an increase of
radiation-induced residual DNA double strand breaks
DNA double strand breaks (DSB) are considered to be the most
severe, life-threatening DNA lesions caused by ionizing radiation
Figure 2. QLT0267 significantly reduces basal cell survival and sensitizes hHNSCC cells to ionizing radiation. (A) For 2D or 3D clonogenic
assays, single cells were plated onto lrECM or inserted into lrECM and exposed to increasing concentrations of QLT0267 (0–20 mM) for 1 h or 24 h.
Colonies were counted microscopically after 8–11 days. Results are means6s.d. (n=3). Student’s t-test compared clonogenic survival of QLT0267-
treatedcellsunder2Dvs.3Dgrowthconditions.*P,0.05.(B)Photographsshowcolonies11days(FaDu)or8days(UTSCC45)aftertreatment withDMSO
or 10 mM QLT0267. (C) Subsequent to a 1-h or a 24-h exposure with DMSO or QLT0267, 2D and 3D cell cultures were irradiated with 2 Gy X-rays. Results
represent means6s.d. (n=3). Student’s t-test compared QLT0267-treated/irradiated vs. DMSO-treated/irradiated cells. *P,0.05; **P,0.01
doi:10.1371/journal.pone.0006434.g002
Table 1. Calculation of enhancement ratios from survival rates
of cells exposed to 2 Gy/DMSO versus 2 Gy/QLT0267 (10 mM).
Enhancement Ratio SF (2 Gy)DMSO/SF(2 Gy)QLT0267
FaDu 1h 2D 1.04679
FaDu 1h 3D 1.03694
FaDu 24h 2D 1.512652
FaDu 24h 3D 2.570918
UTSCC45 1h 2D 0.954046
UTSCC45 1h 3D 0.978272
UTSCC45 24h 2D 1.617318
UTSCC45 24h 3D 1.574609
2D, two-dimensional cell culture; 3D, three-dimensional cell culture.
doi:10.1371/journal.pone.0006434.t001
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QLT0267, we measured the number of residual DSB (=un-
repaired DSB at 24 h after treatment; rDSB) induced by
QLT0267 alone or in combination with 2-Gy irradiation using
the cH2AX/53BP1 foci assay. Analysis of QLT0267 exposure
only revealed a significant (P,0.01) elevation of rDSB in 2D
grown FaDu cells (Figure 3A). In combination with irradiation,
QLT0267-treated 3D FaDu and UTSCC45 cell cultures showed
significantly (P,0.01) more rDSB 24 h after 2 Gy as compared to
DMSO (Figure 3A).
QLT0267 fails to induce apoptosis
Owing to reports showing induction of apoptosis by QLT0267,
the rate of apoptosis was examined upon QLT0267 treatment
with and without irradiation in comparison to DMSO controls. To
note, p53 is deleted in FaDu and mutated in UTSCC45 cells (data
not shown). QLT0267 alone and in combination with irradiation
failed to induce apoptosis in 2D and 3D cultured FaDu and
UTSCC45 cells (Figure 3B).
QLT0267 treatment leads to accumulation of cells in the
G2 cell cycle phase
As cell cycle phases can be associated with different degrees of
radiosensitivity [37,38], we next determined the percentage of cells
in the radiosensitive G2 cell cycle phase upon QLT0267 alone or
in combination with irradiation. The data indicated a significant
(P,0.01) accumulation of G2 cells at 24 h after onset of QLT0267
treatment as compared to DMSO controls (Figure 4A). This effect
could only be observed in 2D FaDu and 2D UTSCC45 cell
cultures. Similarly, irradiation with 6 Gy resulted in a significant
(P,0.01) G2 cell cycle blockage (Figure 4B). Intriguingly, the
combination of QLT0267 plus 6 Gy showed a further significant
(P,0.01) accumulation of cells in the G2 phase under 2D but not
under 3D growth conditions (Figure 4B).
Phosphorylation of Akt, GSK3b, FAK and p44/42 MAPK is
modulated by QLT0267 in a cell culture model-
dependent manner
To examine the downstream effects of QLT0267 on important
prosurvival signaling pathways, the phosphorylation and protein
expression of ILK, FAK, p44/42 MAPK and the putative ILK
downstream targets Akt and Glycogen Synthase Kinase 3b
(GSK3b) were explored. Overall, the QLT0267-related modula-
tion of examined protein kinases showed a great similarity
between both cell lines (Figure 5A and B). In 2D, Akt
Serine(S)473 and focal adhesion kinase (FAK) Tyrosine(Y)397
phosphorylation were strongly reduced by QLT0267 while both
GSK3b S9 and p44/42 MAPK phosphorylation were moder-
ately or greatly induced, respectively (Figure 5A and B). Although
in part significant, the QLT0267-related changes in phosphor-
ylation of examined protein kinases were lower under 3D condi-
tions than under 2D conditions (Figure 5A and B). Expression
Figure 3. QLT0267 treatment increases the number of radiation-induced DSBs without affecting apoptosis. (A) After treatment with
10 mM QLT0267 for 24 h, 2D or 3D lrECM grown cells remained unirradiated or received a single dose of 2 Gy. After 24 h, cells were isolated, fixed and
co-stained against 53BP1 and cH2AX. Double stained foci from 150 cells were microscopically counted per experiment. Number of foci of irradiated
cells was normalized to number of foci of unirradiated cells. Results represent means6s.d. (n=3). Student’s t-test compared QLT0267- vs. DMSO-
treated or QLT0267/2Gy- vs. DMSO/2Gy-treated cells. *P,0.05, **P,0.01. Photographs illustrate immunofluorescence staining of 53BP1 (green) and
cH2AX (red) of 3D grown cell cultures. Nuclei were stained with DAPI (blue). (B) In parallel, cells were treated as indicated, fixed and stained with DAPI
to microscopically determine cells with typically apoptotic nuclear morphology. Results are means6s.d. (n=3).
doi:10.1371/journal.pone.0006434.g003
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treatment.
Treatment with QLT0267 does not antagonize ILK-
mediated radiosensitization
Exogenous expression of a constitutively active form of ILK has
been reported to enhance cellular radiosensitivity in a variety of
human tumor cell models [20,24,26,27]. Therefore, we sought to
evaluate whether treatment of cells with the putative ILK inhibitor
QLT0267 reverses ILK-mediated radiosensitization. Importantly,
QLT0267 caused significant (P,0.01) additional cytotoxicity in
FaDu cells expressing a constitutively active form of ILK (IH43
cells) and failed to diminish/antagonize the enhanced ILK-
mediated radiosensitivity of these cells (Figure 6). From these
findings we conclude that the radiosensitizing effects by QLT0267
are in majority independent from ILK.
QLT0267 modulates radiation survival of mouse
fibroblasts in an ILK-independent manner
To further clarify possible off-target effects of QLT0267,
immortalized ILK
2/2 and ILK-expressing (ILK
floxed/floxed(fl/fl))
fibroblasts were exposed to QLT0267. Intriguingly, QLT0267
significantly (P,0.01) reduced basal cell survival in 2D and in 3D
grown cells concentration-dependently (Figure 7A). ILK
2/2 fibro-
blasts demonstrated a higher susceptibility to QLT0267 than ILK
fl/fl
fibroblasts. The combination of QLT0267 with irradiation led to a
significant (P,0.01) radiosensitization in 2D and 3D fibroblast cell
cultures (Figure 7B). While the phosphorylation of the ILK putative
downstream target Akt remained unaltered in 2D and 3D
QLT0267-treated cultures, GSK3b S9 was marginally dephosphor-
ylated under 3D growth conditions in ILK
fl/fl and ILK
2/2 cells
(Figure 7C). Total protein expression of ILK, Akt and GSK3b
remained unaffected by QLT0267 and DMSO.
siRNA-mediated knockdown of ILK does not alter the
radiosensitivity of FaDu and UTSCC45 hHNSCC cells
Finally, we used a genetic, small interfering (si)RNA-based
approach to eliminate ILK, which might exert different effects on
radiosensitivity than a broad spectrum inhibitor such as QLT0267.
The siRNA-mediated ILK knockdown (78–84% efficiency;
Figure 7D) conveyed no significant changes in the radiosensitivity
of 2D and 3D grown FaDu and UTSCC45 cells as compared to
control siRNA (Figure 7E).
Discussion
In combination with radiotherapy, ILK mediates rigorous
antisurvival effects in a variety of human tumor cell models and in
mouse fibroblasts [20,24–27,39]. Therefore, molecular targeting of
ILK in patients receiving radiotherapy is highly questionable at the
moment. In vitro and in vivo work from others [6,10,14,16,28,40,41],
however, indicate a prosurvival and tumor-promoting function of
ILK, which suggested ILK as potent molecular cancer target.
Moreover, ILK has been considered as protein kinase, which
fostered the development of small molecules against ILK such as
QLT0254 [22], KP-SD-1 [40], KP-SD-2 [41] as well as the
compound QLT0267 [23] used in this work. Preclinical studies with
these components demonstrated tumor growth inhibition and
induction of apoptosis of tumor cells. The present study explored,
Figure 4. QLT0267 and irradiation induce accumulation of G2 phase cells in a cell culture model-dependent manner. (A) After
treatment with QLT0267 for indicated time periods, cells were incubated with BrdU and cell cycle analysis was performed as described under
Materials and Methods. Results are means6s.d. (n=3). Student’s t-test compared QLT0267- vs. DMSO-treated cells. *P,0.05; **P,0.01. (B) Cell cycle
distribution was assayed in cells after a 24-h QLT0267 treatment plus 6 Gy X-rays (FaDu: 12 h post irradiation; UTSCC45: 18 h post irradiation). Results
are means6s.d. (n=3). Student’s t-test compared QLT0267/irradiated vs. DMSO/irradiated cells. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0006434.g004
QLT0267 in Radiosensitization
PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6434for the first time, the cytotoxic and radiosensitizing potential of the
small molecule inhibitor QLT0267 and its dependence on ILK in
hHNSCC cells and ILK
fl/fl and ILK
2/2 mouse fibroblasts. To take
growth conditions into account, we used conventional 2D/
monolayer cell cultures grown on lrECM and more physiological
3D lrECM cell cultures [25,42,43]. The major results are that (i)
QLT0267 effectively reduces ILK kinase activity as well as Akt and
FAK phosphorylation in hHNSCC cells, (ii) QLT0267 enhances the
radiosensitivity of hHNSCC cells and ILK
fl/fl and ILK
2/2 mouse
fibroblasts in an ILK-independent manner, (iii) QLT0267 increases
the number of radiogenic residual DNA double strand breaks, (iv)
QLT0267 fails to induce apoptosis in hHNSCC cells, (v) QLT0267
treatment leads to accumulation of 2D grown cells in the G2 cell
cycle phase, and (vi) QLT0267 does not antagonize ILK-mediated
radiosensitization.
In our hands, the small molecule inhibitor QLT0267 reduced
ILK kinase activity efficiently by 50–75% in the two hHNSCC cell
lines, FaDu and UTSCC45. Concerning the QLT0267-related 3-
fold, unexpected increase in ILK activity in 3D UTSCC45 cell
cultures, it can be speculated that such effects result from trans-
criptional and posttranscriptional modification of signaling path-
waysas well as from changes inprotein-proteininteractions induced
by cell-matrix interactions in the 3D microenvironment. This
adverse effect has also particularly to be taken into consideration on
the basis of the inhibitory spectrum of QLT0267, which still needs
to be determined. Without a correlation between ILK kinase
inhibition and survival, QLT0267 treatment resulted in a concen-
tration- and time-dependent reduction of clonogenic cell survival
under both 2D and 3D growth conditions. In contrast to studies
from other groups examining hHNSCC cell lines [23], a 24-h
exposure with 10 mM QLT0267 did not lead to an elevated
induction of apoptosis in FaDu and UTSCC45 cells, which could
have been linked mechanistically to the declined clonogenic
survival rate.
Intriguingly, the small molecule inhibitor QLT0267 sensitized
the hHNSCC cell lines FaDu and UTSCC45 to the clinically
relevant dose per fraction of 2 Gy X-rays. Although QLT0267-
treated 2D cell cultures showed elevated numbers of cH2AX/
p53BP1-positive foci, which might suggest a modulation of the
DNA repair machinery, there appeared no correlation between
foci number and radiosensitivity under 2D growth conditions. In
contrast, foci number remained unchanged in 3D but significantly
increased in irradiated 3D cell cultures suggesting an effect of
QLT0267 on molecules involved in DNA repair or cell cycling.
The cell cycle analysis revealed that merely 2D cell cultures
exhibited a pronounced increase in G2 phase cells after QLT0267
incubation. Cells in the G2 cell cycle phase are considered more
radiosensitive than cells e.g. in G1 [37,38]. Thus, there appears no
consistent, mechanistic link between the effects of QLT0267 on
rDSB or cell cycling and radiosensitization. Nevertheless, our
Figure 5. QLT0267 differentially modifies phosphorylation of various protein kinases cell culture model-dependently. (A) Following
a 24-h treatment with DMSO (D) or indicated concentrations of QLT0267, 2D or 3D cultured cells were lysed as described under Materials and
Methods. Total protein lysates were subjected to SDS-PAGE and Western blotting with specific antibodies. b-Actin served as loading control. (B)
Protein phosphorylation was analyzed by densitometry and normalized to total protein expression. Results represent means6s.d. (n=3). Student’s t-
test compared QLT0267- vs. DMSO-treated cells. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0006434.g005
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yet to be determined inhibitory spectrum.
Our experiments shed light on this speculation by demonstrat-
ing that e.g. Akt dephosphorylation, as a published readout for
ILK [14], followed a different pattern than the decrease in ILK
kinase activity upon QLT0267. While ILK kinase activity is
similarly reduced by 1 and 10 mM QLT0267, Akt dephosphor-
ylation followed a concentration-effect relationship. The same
holds true for FAK. Supporting data for this notion comes from
our 3D cell cultures. Here, none of the investigated protein kinases
showed a pronounced dephosphorylation. These findings, again,
underscore the impact of a 3D growth environment on signaling
cascades, on protein-protein interactions and on a modulated
inhibitory efficacy of small molecules like QLT0267. Based on
this, the molecular mechanisms whereby QLT0267 mediates its
cytotoxic and radiosensitizing potential cannot be explained at the
moment.
Further approaches exploring the effects of QLT0267 on
radiosensitization employed FaDu cells expressing a constitutively
active form of ILK and mouse ILK
fl/fl and ILK
2/2 fibroblasts. If
ILK mediates radiosensitization, a specific inhibition of ILK kinase
activity through QLT0267 would result in radioprotection
indicated by increased clonogenic cell survival. However, IH43
transfectants expressing a constitutively active form of ILK
responded with enhanced radiosensitivity upon QLT0267. Accord-
ingly, the comparison of ILK
fl/fl and ILK
2/2 fibroblasts revealed a
higher susceptibility of ILK
2/2 cells for QLT0267 in 2D but not in
3D. Interestingly, the QLT0267-mediated radiosensitization as well
as the effects on phosphorylated S473 of Akt and S9 of GSK3b
presented similar in ILK
fl/fl and ILK
2/2 fibroblasts. Finally,
clarification of the importance of ILK for the radiosensitivity of
the tested hHNSCC cell lines in 2D and 3D was performed by ILK
siRNA knockdown. Surprisingly, ILK depletion transduced no
alterations of the clonogenic radiation survival in FaDu and
UTSCC45 cells.
In conclusion, our data identified the small molecule inhibitor
QLT0267 as potent therapeutic to enhance the cellular radiosen-
sitivity of hHNSCC cells. Although strong evidence is presented
that QLT0267 exerts these effects independent from ILK, further
investigations are warranted to define the complete spectrum of
this compound with regard to cancer target specificity and possible
combinations with radiotherapy.
Materials and Methods
Antibodies and reagents
Antibodies against ILK, FAK, GSK3b, 5-bromo-2-deoxyuridine
(BrdU) (BD, Heidelberg, Germany), phospho-Akt Serine(S)473,
Akt, phospho-p44/42 MAPK, p44/42 MAPK, GSK3b S9,
GSK3a/b S21/9 (Cell Signaling, Frankfurt a.M., Germany),
phospho-FAK Tyrosine(Y)397 (Biosource, Solingen, Germany), b-
Actin (Sigma, Taufkirchen, Germany), phospho-Histon H2AX-
S139(Upstate,Hamburg,Germany),p53bindingprotein 1(53BP1)
(Novus, Littleton, USA), horseradish peroxidase-conjugated donkey
anti-rabbit and sheep anti-mouse (Amersham, Freiburg, Germany),
Alexa594 anti-mouse and Alexa488 anti-rabbit (Invitrogen, Karls-
ruhe, Germany) were purchased as indicated. Enhanced chemilu-
minescent reagent (ECL) was from Amersham, G418 from
Calbiochem (Bad Soden, Germany), oligofectamine from Invitro-
gen and dimethyl sulfoxide (DMSO) from Applichem (Darmstadt,
Germany). BrdU was from Serva (Heidelberg, Germany), RNase A
type III-A from Sigma and pepsin 0.7 FIP-U from Merck
(Darmstadt, Germany). Vectashield/DAPI mounting medium was
from Alexis (Gru ¨nberg, Germany).
Cell culture and radiation exposure
FaDu hHNSCC cells were kindly provided from M. Baumann
(Dresden University of Technology, Germany) and stably
transfected with pUSEamp vectors (Upstate, Hamburg, Germany)
containing a cDNA construct encoding for ILK-hyperactive kinase
(hk) or empty vector (pUSEamp) as published [27]. UTSCC45
hHNSCC cells were kindly provided from R. Grenman (Turku
University Central Hospital, Finland). ILK
fl/fl and ILK
2/2
immortalized mouse fibroblasts were kindly provided from R.
Fa ¨ssler (MPI, Martinsried, Germany; [44]). Cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) containing gluta-
max-I supplemented with 10% fetal calf serum and 1% non-
essential amino acids (PAA, Co ¨lbe, Germany) at 37uCi na
humidified atmosphere containing 10% CO2 (pH 7.4). In all
experiments, asynchronously growing cells were used. Irradiation
was delivered at room temperature using single doses of 200 kV
X-rays (Yxlon Y.TU 320; Yxlon, Copenhagen, Denmark) filtered
with 0.5 mm Cu. The absorbed dose was measured using a
Duplex dosimeter (PTW, Freiburg, Germany). The dose-rate was
approximately 1.3 Gy/min at 20 mA and applied doses ranged
from 0 to 6 Gy.
ILK kinase inhibition by QLT0267
QLT0267, obtained from QLT, Inc. (Vancouver, Canada), is
an inhibitor of serine/threonine kinases with high preference for
ILK [35]. QLT0267 was dissolved in DMSO to a concentration of
40 mM and stored at 280uC.
Colony formation assay under 2D and 3D cell culture
conditions
The 2D colony formation assay was applied for measurement of
clonogenic cell survival as published [20]. Under two-dimensional
conditions, cells were grown on laminin-rich extracellular matrix
(lrECM, Matrigel; 1 mg/cm
2; BD) for 24 h. Prior to irradiation
Figure 6. QLT0267 fails to antagonize the radiosensitization
mediated by a constitutively active form of ILK. FaDu cells stably
transfected with a constitutively active form of ILK (IH43) or control
vector (EV2) were used. Cells cultured in 2D or 3D were exposed to
1 mMo r1 0mM QLT0267 for 24 h and irradiated with 2 Gy X-rays.
Results are means6s.d. (n=3). Student’s t-test compared QLT0267/2Gy-
vs. DMSO/2Gy-treated cells. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0006434.g006
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QLT0267 (1–10 mM) or DMSO as control for 24 h. After 8 days,
cells were stained with Coomassie blue and cell colonies (.50 cells)
were counted. To evaluate clonogenic survival under three-
dimensional conditions [25], single cells were grown in 0.5 mg/ml
lrECM for 24 h prior to treatment with QLT0267 and irradiation.
According to 2D clonogenic assays, cell clusters with a minimum
of 50 cells were microscopically counted 8 to 11 days after plating.
Plating efficiencies were calculated as follows: numbers of colonies
formed/numbers of cells plated. Surviving fractions (SF) were
calculated as follows: numbers of colonies formed/(numbers of
cells plated (irradiated)6plating efficiency (unirradiated)). Each
point on survival curves represents the mean surviving fraction
from at least three independent experiments. Enhancement ratios
were calculated as follows: SF (2 Gy)DMSO/SF(2 Gy)QLT0267.
Total protein extracts and Western Blotting
Cells grown either on lrECM or in lrECM were incubated with
QLT0267 (1–10 mM) or DMSO as control. In 2D, cells were
rinsed with ice-cold PBS prior to adding modified RIPA buffer
(50 mM Tris-HCl (pH 7.4), 1% Nonidet-P40, 0.25% sodium
deoxycholate, 150 mM NaCl, 1 mM EDTA, Complete protease
inhibitor cocktail (Roche, Mannheim, Germany), 1 mM NaVO4,
2 mM NaF) and samples were harvested by scraping. In 3D, cells
were lysed in 3D lrECM using modified RIPA buffer. Samples
were stored at 280uC. Total protein amounts were measured with
the BCA assay (Pierce, Bonn, Germany). After SDS-PAGE and
transfer of proteins onto nitrocellulose membranes (Schleicher and
Schuell, Dassel, Germany), probing and detection of specific
proteins was accomplished with indicated antibodies and ECL as
described [24].
ILK kinase activity assay
ILK kinase activity was determined as published previously
[45]. In brief, cell lysis was performed using cell lysis buffer (Cell
Signaling, Frankfurt a.M., Germany) supplemented with Com-
plete protease inhibitor cocktail. Then, cells were scraped off and
500 mg of total protein were incubated with protein-G-agarose
Figure 7. Modification of clonogenic survival and protein phosphorylation by QLT0267 are independent from ILK. Mouse ILK
fl/fl and
ILK
2/2 fibroblasts were cultured under 2D or 3D cell culture conditions, exposed to QLT0267 for 24 h plus/minus irradiation (2 Gy X-rays) and basal
(A) and radiation cell survival (B) were measured as described under Materials and Methods. Results are means6s.d. (n=3). Student’s t-test compared
QLT0267-treated ILK
2/2 vs. QLT0267-treated ILK
fl/fl cells (A) or QLT0267/irradiated vs. DMSO/irradiated cells (B). *P,0.05; **P,0.01. (C) Total protein
lysates from QLT0267- or DMSO-treated cells were analyzed by SDS-PAGE and Western blotting using indicated antibodies. (D) Cells were transfected
with 20 nM ILK-specific siRNA or control siRNA. At 48 h post transfection, efficient downregulation of ILK expression was confirmed by Western
blotting. Densitometric values were normalized to b-Actin. (E) For clonogenic assays, siRNA knockdown cell cultures were irradiated with 2 Gy X-rays
48 h after transfection. Results represent means6s.d. (n=3).
doi:10.1371/journal.pone.0006434.g007
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Heidelberg, Germany) for 24 h at 4uC. Immunoprecipitated ILK
was used for protein kinase activity measurements using kinase
buffer plus glycogen synthase kinase (GSK)-fusion protein and
200 mM adenosine triphosphate according to the manufacturer’s
protocol (Cell Signaling, Frankfurt a.M., Germany). After 30 min
incubation at 30uC, the reaction was terminated with 3X sodium
dodecyl sulfate (SDS) sample buffer. Subsequent to SDS-PAGE
and Western blotting, ILK kinase activity was measured by
detection of phosphorylated GSK fusion protein using GSK3a/b
S21/9 antibodies.
Immunofluorescence staining
For detection of residual DNA-double strand breaks (rDNA-
DSBs) the phosphorylated H2AX (cH2AX)/p53 binding protein-1
(53BP1) focus assay [46] was performed. Cells were grown either
on or in lrECM for 24 h, irradiated with 0 or 2 Gy and isolated
24 h thereafter using 5 mM EDTA/PBS and trypsin on ice. After
cytospin, cells were fixed with 1% formaldehyde/PBS and
permeabilized with 0.25% Triton X-100/PBS. Staining was
accomplished with specific anti-cH2AX and anti-53BP1 antibod-
ies and Vectashield/DAPI mounting medium. cH2AX/53BP1-
positive nuclear foci of at least 150 cells from three independent
experiments were counted microscopically with an Axioscope
2plus fluorescence microscope (Zeiss) and defined as rDSBs.
Radiation-induced foci were calculated as follows: number of
fociirradiated – number of fociunirradiated.
DAPI staining for apoptosis
Twenty-four hours prior to a 2-Gy radiation, cells were
incubated with QLT0267 (10 mM) or DMSO. After 8 h, cells
were washed with 0.9% NaCl (Roth, Karlsruhe, Germany), fixed
and permeabilized using 4% paraformaldehyde/0.1% Triton X-
100 (Merck, Darmstadt, Germany) and stained with Vectashield/
DAPI mounting medium. At least 300 cells were counted from
three independent experiments.
siRNA-mediated ILK knockdown
ILK siRNA (sequence: 59- GGGCAAUGACAUUGUCGUGtt
-39) was obtained from Applied Biosystems (Darmstadt, Germany).
Ambion negative control siRNA #1 (Applied Biosystems) was
used as nonspecific control. Cells were plated into 6-well plates
24 h prior to transfection. siRNA delivery was accomplished with
oligofectamine under serum-free conditions at a concentration of
20 nM for 8 h as published [20]. Twenty-four hours after
transfection, cells were trypsinized and transferred to lrECM
either for colony formation assays or Western blotting.
Cell cycle analysis
2D and 3D cell cultures were treated with 10 mM QLT0267 (or
DMSO control), with 6 Gy X-rays or the combination of both.
QLT0267-treated cells were harvested after a 24-h treatment time.
Cells irradiated with 6 Gy were harvested after 12 h (FaDu) or
18 h (UTSCC45). In the combined regime, cells were harvested
after 36 h (FaDu: 24-h QLT0267 plus 12 h 6 Gy) or 42 h
(UTSCC45: 24-h QLT0267 plus 18 h 6 Gy). Prior to cell isolation
with trypsin and 5 mM EDTA/PBS on ice, cells were incubated
with 10 mM BrdU for 10 min (2D) or 30 min (3D). Then, cells
were prepared for cell cycle analysis as published [24]. Detection
of BrdU was accomplished with anti-BrdU and anti-mouse IgG
FITC antibodies and total DNA staining with propidium iodide
(PI) solution. Acquisition of data for 50,000 events was performed
with a CyFlow (Partec, Mu ¨nster, Germany). The distribution of
cells in the different phases of the cell cycle was analyzed from the
DNA-dot-blots and -histograms using FloMax software.
Data analysis
Means6SD of at least three independent experiments were
calculated with reference to untreated controls defined in a 1.0
scale. To test statistical significance, Student’s t test was performed
using Microsoft
H Excel 2003. Results were considered statistically
significant if a P-value of less than 0.05 was reached.
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